Stéphane Bancel reveals Phase 3 mRNA trial success
- Moderna Phase 3 trials show personalized mRNA vaccines prevent melanoma recurrence after five years.
- Algorithms select 34 patient-specific mutations, printing customized doses in automated fridge-sized modules.
- Moderna is expanding the platform to target lung cancer, pancreatic tumors, and autoimmune diseases.
Oncology spent two decades failing to build effective cancer vaccines. Moderna just broke the streak.
Speaking on The a16z Show in September 2026, Moderna chief executive officer Stéphane Bancel presented Phase 3 trial results demonstrating that the company's individualized mRNA vaccine meets primary recurrence-free survival endpoints in melanoma patients. Long-term Phase 2 data showed 80% of treated subjects remained disease-free after five years. Standard immunotherapies like Keytruda remove natural molecular brakes on immune response, but fail in 40% of cases while inducing harsh autoimmune side effects. Moderna takes an orthogonal approach.
"Mass-produced cancer vaccines failed because tumor targets are overwhelmingly unique."
- Stéphane Bancel, The a16z Show
By comparing sequence data from tumor DNA against healthy tissue, an algorithm isolates up to 34 patient-specific mutations to construct a synthetic mRNA molecule. Bancel noted that 90% of selected targets differ between individual patients. Mass-produced treatments miss these targets because cancer mutations are rarely uniform. Customization is the fundamental mechanism driving the therapy's success.
Making single-dose treatments for thousands of patients shatters standard pharmaceutical manufacturing models. Instead of relying on massive bioreactors or cell cultures, Moderna developed enzymatic synthesis modules operating in water. These fridge-sized units shrink the production footprint while speeding up output.
The complete pipeline turns a tissue biopsy into an injectable drug in 42 days. Rather than evaluating each bespoke dose individually, the FDA regulates the automated pipeline under a process Biologics License Application. This regulatory framework tests whether uniform process inputs reliably yield safe outcomes, setting the blueprint for future synthetic therapeutics.
Melanoma represents only the initial baseline for the platform. Moderna is deploying trials for lung, kidney, and bladder cancers, including standalone monotherapy for early-stage lung tumors. For treatment-resistant pancreatic and gastric cancers, pairing mRNA doses with small molecules forces new T-cell creation.
The company is also adapting the technology to treat pediatric liver conditions and autoimmune disorders. Instead of suppressing immune function with lifelong systemic drugs, the platform trains T-cells to clear rogue immune cells. Custom genetic instruction is replacing broad chemical suppression.